Estraderm MX is a medicine containing the active ingredient(s) estradiol. On this page you will find out more about Estraderm MX, including side effects, age restrictions, food interactions and whether the medicine is subsidised by the government on the pharmaceutical benefits scheme (PBS)
Active ingredient in this medicine: estradiol
Pack size information
Please select the pack size from the options directly below to view information on the medicine.
Information for medicine and pack size:
Estraderm MX 75 microgram/24 hours patch, 2
Consumer Medicine Information leaflet:
No consumer medicine information leaflet was found for the pack size you selected. It may be unavailable or there may be a technical problem. You should speak to your pharmacist, healthcare professional, or call healthdirect on 1800 022 222 for more information.
What this medicine is for
Menopausal symptoms: Short-term treatment of signs and symptoms of oestrogen deficiency due to menopause, whether natural or surgically induced. In women with an intact uterus, oestrogen should always be opposed by progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals (Refer to CLINICAL TRIALS and DOSAGE AND ADMINISTRATION). Prevention of post-menopausal bone mineral density loss: Estraderm MX 50, 75 and 100 may be used for prevention of post-menopausal bone mineral density loss in women with an increased risk of future osteoporotic fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of bone mineral density loss. When prescribed solely for the prevention of postmenopausal bone mineral density loss, therapy should only be prescribed for women who are at high risk of future fracture and who are intolerant of, or contraindicated for, non-oestrogen products approved for prevention of bone mineral density loss. Lifestyle modifications and the risk-benefit profile of Estraderm MX should be taken into careful consideration and discussed with the patient to allow the patient to make an informed decision prior to prescribing( See PRECAUTIONS and DOSAGE AND ADMINISTRATION). Combination HRT should not be used in hysterectomised women because it is not needed in these women and it may increase risk of breast cancer.
Table of characteristics
|Visual appearance||A translucent, colourless system, about 6.1cm in diameter, square, with rounded corners, on an oversized transparent protective liner. The backing film is imprinted with code "CG HKH".|
|Dosage Form||Drug delivery system, transdermal|
|Route of administration||Transdermal|
2 starter pack: Prescription Only Medicine, or Prescription Animal Remedy
24: Prescription Only Medicine, or Prescription Animal Remedy
8: Prescription Only Medicine, or Prescription Animal Remedy
There is one type of pack available.
Pack type 1
|Storage temperature||Store below 25 degrees Celsius|
|Storage conditions||No information available|
|Life time||2 Years|
We were unable to verify that this medicine is available on the PBS (Pharmaceutical Benefits Scheme). Please consult your pharmacist if you need further information
The PBS provides a list of government subsidised medicines available to be dispensed to patients. Further information can be found on the Pharmaceutical Benefits Scheme website.
Is this medication banned in sport?
Check if you can use your medicine whilst playing sport. Search the Australian Sports Anti-Doping Authority (ASADA) database that provides information about the prohibited status of specific medications and/or the active ingredient based on the current World Anti-Doping Agency (WADA) Prohibited List.